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49 DIURNAL PLASMA-ACTH-LEVELS IN CORTICOSTEROID TREATED 
PATIENTS WITH CONGENITAL ADRENAL HYPERPLASIA (CAH) . 2 
O.A.Müller\ R.Fink , P.C.Scriba , J.Weil ,F^ Bidlingmaier 
and D.ffnorr . Medizinische K l i n i k Innenstadt and Kinder-
K l i n i k , U n i v e r s i t a e t Muenchen, FRG. 
The t h e r a p e u t i c a l c o n t r o l of CAH-patients by measuring a 
s i n g l e parameter of the s t e r o i d hormones i s c o n t r o v e r s i a l . The 
measurement of d i f f e r e n t adrenal androgens has not given the 
awaited u s e f u l r e s u l t s (1). The same has been seen f o r s i n g l e 
plasma-ACTH-levels (2). This study has measurgd thg oplasma-ACTH-
l e v e l s at d i f f e r e n t times during the day (08 ,12 ,18 ,24 ) 
to assess the t h e r a p e u t i c a l value o f 2 d i f f e r e n t c o r t i c o s t e r o i d s , 
c o r ^ j s o l ^F) and Qprednisone (P), usu a l l y given 3 times d a i l y 
(08 ,13 ,21 ). In a d d i t i o n , in the pat i e n t s with s a l t l o s s , 
9 a - F - c o r t i s o l was given. The d i u r n a l v a r i a t i o n of plasma-ACTH 
and 17ct-0H-progesterone (17-OHP) and F was examined i n 20 pa-
t i e n t s , 9 of which were re-examined a f t e r a l t e r a t i o n of therapy. 
Plasma-ACTH was measured by radioimmunoassay (RIA) a f t e r extrac-
t i o n (3). Plasma s t e r o i d s were measured by RIA a f t e r p r i o r 
chromatography on Sephadex LH-20 columns (4). 
RESULTS : ACTH-levels were on the whole glevated, with maximal 
values at 08°°, f a l l i n g to a minimum at 24 °. There was a s i g n i -
f i c a n t c o r r e l a t i o n between ACTH-levels and 17-OHP (n=114) a f t e r 
a logarithmic transformation (r=0.639, p<0.001) and an inverse 
c o r r e l a t i o n between ACTH and F (n=114, r= -0.255, p<0.01). For a 
b e t t e r comparison between d i f f e r e n t p a t i e n t s , the i n t e g r a l (I) 
under the ACTH curve over a 24h period was used (1= J " 2 4 ACTH (t) 
dt = X pg/ml ACTH). The value of I in CAH-patients ï n most cases' 
was much higher than in normals (I: 400-900, n=4). In F-treated 
p a t i e n t s I ranged from 220-8000 (n=17), in P-treated patients 
from 580-12100 (n=12), which was no s i g n i f i c a n t d i f f e r e n c e . The 
r a t i o F:P (given dose in mg) was 4-5 : 1. A better comparison i s 
obtained when I was c a l c u l a t e d f o r each p a t i e n t , who has under-
gone both F and P treatment (n=5). In 4 of these p a t i e n t s I i s 
much lower under F, whereas in the remaining one, under 12.5 mg 
F/day I = 5700, under 3 mg P/day I = 2573. In a f u r t h e r 4 pa-
t i e n t s under d i f f e r i n g doses of the same c o r t i c o s t e r o i d i t was 
oo 
found that in p a r t i c u l a r the evening dose (21 ) must not be too 
low, otherwise the ACTH-level on the following day (08 ) was 
exc e s s i v e l y high. 
CONCLUSION : The use of the ACTH-24h-integral, as described 
here, appears to be promising in the evaluation of therapy in 
CAH-patients. Furthermore the use of t h i s parameter in the same 
pat i e n t s r e c e i v i n g d i f f e r e n t c o r t i c o s t e r o i d s helps in the choice 
of t h e i r "optimal" medication. 
+ Supported by the Deutsche Forschungsgemeinschaft (Sonder-
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